Skip to main content

Table 3 Comparison of HRCT findings between patients with and without anti-CADM-antibody

From: Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?

  MDA-5 positive MDA-5 negative p value
(n = 10) (n = 6)
Distribution
 Upper lobe dominant 1 (10 %) 0 1.00
 Lower lobe dominant 9 (90 %) 6 (100 %) 1.00
 Peribronchovascular 2 (20 %) 4 (67 %) 0.118
 Subpleural 8 (80 %) 2 (33 %) 0.118
Main findings
 Consolidation 1 (10 %) 5 (83 %) 0.00762
 Ground glass opacity 5 (50 %) 0 0.0934
 Reticulation 1 (10 %) 0 1.00
 Irregular linear opacity 3 (30 %) 1 (17 %) 1.00
Additional findings
 Traction bronchiectasis 5 (50 %) 4 (67 %) 0.633
 Cyst 0 1 (17 %) 0.375
 Subpleural curve linear shadow 4 (40 %) 3 (50 %) 1.00
 Thickening of interlobular septa 2 (20 %) 2 (33 %) 0.604
 Emphysema 1 (10 %) 1 (17 %) 1.00
 Volume loss 9 (90 %) 5 (83 %) 1.00
  1. Categorical data are presented as numbers (percentages) and were analyzed using Fisher’s exact test
  2. Abbreviations: CADM clinically amyopathic dermatomyositis, HRCT high-resolution computed tomography, MDA-5, anti-melanoma differentiation-associated gene 5